GlassScriptPhysician profile
Nathaniel R Pasmanter
NPI 1952045403
$1,114.66
in general payments reported to CMS, 2019-2025
18 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $263 · 2023: $239 · 2024: $181 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.24 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $129.55 | 2023-2025 | |
| Ucb, INC. | $117.31 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Sk Life Science, INC. | $107.38 | 2022-2023 | |
| Biogen, INC. | $100.55 | 2023-2025 | Tysabri, Vumerity, Skyclarys |
| Neurelis, INC. | $93.74 | 2022-2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $60.22 | 2025 | Hyqvia |
| Genentech USA, INC. | $59.66 | 2024-2025 | Evrysdi, Ocrevus, Enspryng |
| Eisai INC. | $54.24 | 2025 | |
| Argenx US, INC. | $51.81 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Aucta Pharmaceuticals, INC. | $48.16 | 2025 | Motpoly Xr |
| Jazz Pharmaceuticals INC. | $40.26 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $23.44 | 2025 | Inbrija |
| Vanda Pharmaceuticals INC. | $21.72 | 2025 | Ponvory |
| Acadia Pharmaceuticals INC | $17.38 | 2024 | Nuplazid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $16.56 | 2023 | Cala Kiq, Cala Trio |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.39 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $15.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Pasmanter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.